Apr 22, 2022 8:30am EDT

Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

Apr 19, 2022 4:20pm EDT

Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference

Mar 09, 2022 8:00am EST

Medexus to Participate in the 34th Annual Roth Conference

Mar 01, 2022 7:15am EST

Medexus Pharmaceuticals Announces Deal for Gleolan in the United States

Feb 14, 2022 8:00am EST

Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures

Feb 09, 2022 6:30pm EST

Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021

Feb 01, 2022 4:15pm EST

Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference

Jan 31, 2022 8:00am EST

Medexus Schedules Third Quarter Fiscal 2022 Conference Call

Jan 07, 2022 9:00am EST

Medexus to Present at the H.C. Wainwright BioConnect 2022 Conference

Dec 02, 2021 4:15pm EST

Medexus to Participate in Two Upcoming Virtual Investor Conferences